Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Adjuvant Chemotherapy vs Observation in High Risk Stage Ib Lung Adenocarcinoma
NCT02281708Phase 3Unknown
- Sponsor
- Seoul National University Hospital
- Start
- Oct 2014
- Primary completion
- Sep 2018
- Modality
- Nanoparticles, Small Molecules
- Countries
- 1
01
Overview
Phase 3, randomised, open-label trial of vinorelbine and Cisplatin micelle injection (HA132) in lung adenocarcinoma (3 arms), sponsored by Seoul National University Hospital. Primary endpoint: Disease-Free Survival at 3 years. Status: unknown.
02
Drugs
vinorelbineCisplatin micelle injection (HA132)
03
Conditions
lung adenocarcinoma
Beyond the preview
Go deeper on NCT02281708.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT02281708.